Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, December 5, 2012 - BAT


Submission Type: BLA    Submission ID: 125462/0    Office: OBRR
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) (Equine)
Cangene Corporation
Telecon Date/Time: 05-Dec-2012 09:46 AM        Initiated by FDA? No
Telephone Number:
Communication Categorie(s):
1. Information Request
Telecon Summary:
Request for clarification on: 1) ownership of donor horse herd; 2) responsibility for immunization program; 3) quality agreements related to questions 1 and 2.
FDA Participants: None
Non-FDA Participants: None
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
Requested clarification on the horse herd used as a plasma source for the production of HBAT (aka NP-018, eBAT, BAT). Asked Cangene to provide details on 1) the ownership of donor horse herd (Cangene or USG); 2) responsibility for immunization program (currently performed by Auburn University personnel); 3) quality agreements related to questions 1 and 2.

Page Last Updated: 06/24/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English